1. Home
  2. TRX vs EDIT Comparison

TRX vs EDIT Comparison

Compare TRX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

HOLD

Current Price

$0.80

Market Cap

403.8M

Sector

N/A

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.66

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRX
EDIT
Founded
1990
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
403.8M
432.8M
IPO Year
2002
2016

Fundamental Metrics

Financial Performance
Metric
TRX
EDIT
Price
$0.80
$2.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$1.70
$5.30
AVG Volume (30 Days)
1.4M
2.0M
Earning Date
04-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$84.84
N/A
Revenue Next Year
$96.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$0.33
$1.66
52 Week High
$2.80
$4.54

Technical Indicators

Market Signals
Indicator
TRX
EDIT
Relative Strength Index (RSI) 42.06 37.75
Support Level $0.68 $2.36
Resistance Level $0.89 $2.73
Average True Range (ATR) 0.05 0.17
MACD 0.01 -0.07
Stochastic Oscillator 39.49 10.53

Price Performance

Historical Comparison
TRX
EDIT

About TRX TRX Gold Corporation

TRX Gold Corp is engaged in the exploration, development, and production of mineral property interests in the United Republic of Tanzania, focused on development and mining operations, and on exploring and evaluating its mineral properties. The business of exploring and mining for minerals involves a high degree of risk, and the underlying value of the mineral properties depends on the existence and economic recovery of mineral resources and reserves, as well as the ability to raise long-term financing to continue development. The company is focused on the Buckreef Gold Project, which comprises five prospects: Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba, and includes three main mineralized zones: Buckreef South, Buckreef Main, and Buckreef North.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: